SummaryIndia’s first dengue vaccine, DengiAll, is in phase-3 clinical trials. Developed by Panacea Biotec and ICMR, the vaccine aims to offer comprehensive protection against dengue, potentially transforming public health outcomes and reducing the disease’s impact.